Aptevo Therapeutics Inc APVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if APVO is a good fit for your portfolio.
News
-
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
-
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
-
Aptevo Therapeutics Provides Pipeline Update
-
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
-
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
-
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
-
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
Trading Information
- Previous Close Price
- $0.68
- Day Range
- $0.67–0.71
- 52-Week Range
- $0.67–91.96
- Bid/Ask
- $0.67 / $0.69
- Market Cap
- $2.44 Mil
- Volume/Avg
- 341,360 / 300,126
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 40
Valuation
|
Metric
|
APVO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.03 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
APVO
|
|---|---|
Quick Ratio | 2.34 |
Current Ratio | 2.64 |
Interest Coverage | — |
Quick Ratio
APVO
Profitability
|
Metric
|
APVO
|
|---|---|
Return on Assets (Normalized) | −86.98% |
Return on Equity (Normalized) | −154.62% |
Return on Invested Capital (Normalized) | −111.96% |
Return on Assets
APVO
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Jqpnwhqpgf | Prypj | $562.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Rkdwvjmn | Cpsmj | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Rfcrgrpq | Kkppt | $99.5 Bil | |
MRNA
| Moderna Inc | Qwhfkbw | Gbpmn | $38.8 Bil | |
ARGX
| argenx SE ADR | Pcrjvjkw | Sjzc | $22.3 Bil | |
BNTX
| BioNTech SE ADR | Ckknmvh | Zgjc | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Hjxscmmwf | Stfqwnd | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jgxpqzvz | Tzmxvh | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Pxvnkljhj | Bvccyj | $12.5 Bil | |
INCY
| Incyte Corp | Sjgppmvmd | Yhldksw | $11.6 Bil |